Comparing the Effectiveness of Test and Treat Approaches with Doxycycline or Moxidectin plus Albendazole versus Mass Drug Administration with Ivermectin plus Albendazole for Targeted Elimination of Lymphatic Filariasis in Ghana and Tanzania - aPhase III Clinical Trial

开始日期2024-10-01

申办/合作机构-

NCT05500326 / Not yet recruiting临床2期IIT

Ivermectin Therapy for Scabies Infection in Children Younger Than 5 Years of Age (ITCHY Study)

This is an open label prospective pharmacokinetic single arm study in Laos PDR. This study will be embedded within a cluster-randomized controlled trial of interventions to address childhood undernutrition (SUANHOAM Trial, ACTRN12620000520932) and involves a collaboration with the Murdoch Children's Research Institute, Burnet institute and Lao Tropical and Public Health Institute.
ITCHY Study:
The primary objective is to determine in young children aged 2 to <5 years and weighing 10 to <15 kg if an ivermectin dose of 3 mg achieves comparable drug exposures to the recommended dose in older children. It aims to provide reliable evidence for a safe and effective dose of ivermectin in young children who are especially vulnerable to scabies infections and the associated secondary complications.
ITCHY2 Study:
An embedded phase 2 multicentre, open label prospective pharmacokinetic study in Laos PDR of ITCHY Study. The primary objective is to determine the plasma ivermectin drug exposure in children aged 3 months to 2 years and weighing ≥2 kg receiving an age specific ivermectin dose.

开始日期2024-10-01

申办/合作机构

Murdoch Childrens Research Institute

[+1]

100 项与 GluCls 相关的临床结果

登录后查看更多信息

100 项与 GluCls 相关的转化医学

登录后查看更多信息

0 项与 GluCls 相关的专利（医药）

登录后查看更多信息

309

项与 GluCls 相关的文献（医药）

2024-08-12·Journal of Economic Entomology

Frequencies of insecticide resistance mutations detected by the amplicon sequencing in Plutella xylostella (Lepidoptera: Plutellidae) and Spodoptera exigua (Lepidoptera: Noctuidae) from China

Article

作者: Liu, Zheming ; Zhu, Hang ; Liu, Jia ; Zhou, Xiaomao ; Li, Kaiqin ; Zhou, Yong ; Ma, Haihao ; Man, Yilong ; Liu, Zhangyang

AbstractThe globally prevalent pests, Diamondback moth, Plutella xylostella (Lepidoptera: Plutellidae) and Beet armyworm, Spodoptera exigua (Lepidoptera: Noctuidae), pose significant threats to cruciferous vegetables. They have rapidly developed resistance to a wide range of insecticides, leading to significant yield losses and increased control expenses. In this study, we have established an efficient approach utilizing amplicon sequencing to detect the frequency of 15 target resistance mutant sites in 6 molecular targets, acetylcholinesterase 1 (ACE1), chitin synthase 1 (CHS1), the γ-aminobutyric acid receptor (GABAR), glutamate-gated chloride channel (GluCl), voltage-gated sodium channels (NaV), and ryanodine receptor (RyR) in P. xylostella and the frequency of 11 mutations in 5 molecular targets (except GluCl) in S. exigua in China. Our findings indicate that P. xylostella exhibits remarkably high frequency (over 88.67%) in pyrethroid resistance-related mutations T929I and L1014F of NaV. In S. exigua, the frequencies of L659F mutation were ranging from 41.92% to 74.89%. In addition, the organophosphorus resistance-related mutations A298S and G324A of ACE1 were detected at frequencies ranging from 34.29% to 75.66%, and these 2 mutations occurred simultaneously (from 29.22% to 65.79%) in P. xylostella. An interannual variation in mutation frequency from 2019 to 2021 was found for P. xylostella in HNCS. The frequency of A298S and G324A mutations steadily increased while the frequency of G4946E and I4790M mutations continuously decreased. These results unveil a worrisome scenario of multiple resistance sites in these 2 pests in China and provide valuable insights for the practical application of pesticides in the field.

2024-08-01·American Journal of Physiology-Cell Physiology

TRPV4 and chloride channels mediate volume sensing in trabecular meshwork cells

Article

作者: Tseng, Yun Ting ; Yarishkin, Oleg ; Kuhn, Megan ; Križaj, David ; Lakk, Monika ; Rudzitis, Christopher N. ; Stamer, W. Daniel ; Baumann, Jackson M. ; De Ieso, Michael L.

Intraocular pressure is dynamically regulated by the flow of aqueous humor through paracellular passages within the trabecular meshwork (TM). This study shows hypotonic gradients that expand the TM cell volume and reduce the outflow facility in mouse eyes. The swelling-induced current consists of TRPV4 and chloride components, with TRPV4 as a driver of swelling-induced calcium signaling. TRPV4 inhibition reduced swelling, suggesting a novel treatment for trabeculitis and glaucoma.

2024-07-01·Chemistry & Biodiversity

Design, Synthesis and Insecticidal Activity of Novel meta‐Diamide Compounds Containing Pyridine Rings

Article

作者: Yao, Yanyu ; Li, Kangming ; Liu, Jiyong ; Gong, Hang ; Zhao, Tingting ; He, Zhen ; Zhou, Liqi

AbstractIn order to discover new meta‐diamide compounds with good activity and novel structure, 15 related compounds were designed and synthesized by the bioisosterism principle with cyproflanilide as the lead compound. The insecticidal activities of these compounds against Plutella xylostella and Tetranychus cinnabarinus were tested, and the results of biological activity test showed that some compounds had more than 90 % insecticidal activity against Plutella xylostella at 1 mg/L and Tetranychus cinnabarinus at 100 mg/L. Especially, N‐(2‐bromo‐6‐(difluoromethoxy)‐4‐(perfluoro propan‐2‐yl)phenyl)‐6‐(isonicotinamido)picolinamide against Tetranychus cinnabarinus at 10 mg/L was 100 %, which was better than that of cyproflanilide. Molecular docking studies suggested that N‐(2‐bromo‐6‐(difluoromethoxy)‐4‐(perfluoropropan‐2‐yl)phenyl)‐6‐(4‐cyano‐2‐methylbenzamido)picolinamide had a closely combined with the Plutella xylostella 3RHW (a glutamate‐gated chloride channel). This study provides an avenue for designing and synthesizing a new generation of more effective pesticides.

项与 GluCls 相关的新闻（医药）

2024-03-28

·Pharma CMC

远大医药1500万美元首付款引进一款创新眼用制剂！

3月27日晚，远大医药发布公告，本集团与联拓生物科技有限公司和TarsusPharmaceuticals,Inc.(「Tarsus」)达成产品引进战略合作协议。在相关条件获得满足后，远大医药将以1500万美元的首付款及一定金额的注册里程碑费用为代价取得用于治疗蠕形螨睑缘炎及蠕形螨导致的睑板腺功能障碍的全球创新眼用制剂TP-03在大中华区（中国大陆、中国香港特别行政区、中国澳门特别行政区、台湾地区）的独家开发、生产及商业化权益。此次战略合作将深化本集团在眼科领域的产品布局。TP-03是一款对γ-氨基丁酸门控氯离子通道(「GABA-Cl」)具有选择性的非竞争性拮抗剂，其通过选择性抑制蠕形螨体内的GABA-Cl，使虫体麻痹和死亡，进而彻底治愈蠕形螨睑缘炎。此外，TP-03具有高度亲脂性，可促进其在螨虫栖息的睫毛毛囊油脂中的吸收。TP-03已在美国完成了两项关键性临床研究，共入组800余名蠕形螨睑缘炎患者，根据临床结果显示，两项研究均达到了主要终点和所有次要终点，具有统计学意义，且未发生与治疗相关的严重不良事件。该产品已于二零二三年七月获得美国食品药品监督管理局(「FDA」)批准上市，是目前FDA批准的首款也是唯一一款针对蠕形螨睑缘炎的药物。此外，TP-03在美国开展的用于治疗蠕形螨导致的睑板腺功能障碍的II期临床研究也显示出了阳性的顶线结果。中国注册方面，TP-03已完成了III期临床研究，根据研究结果显示，与对照组相比，TP-03治疗蠕形螨睑缘炎患者的蠕形螨感染根除率具有统计学显著性(p<0.001)，眼睑袖套状分泌物治愈率也呈现出阳性但无统计学意义的趋势(p=0.15)。此外，TP-03耐受性良好，其安全性特征与其它大规模临床试验中观察到的结果相似，无治疗相关的停药情况。本次交易完成后，远大医药将大力推进TP-03在中国的注册落地工作，尽早惠及广大蠕形螨睑缘炎患者。来源：远大医药公告

临床3期上市批准引进/卖出